glucagon like peptide 1 glp 1 receptor agonist medications PDB-101: Molecule of the Month: GLP-1 Agonists Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic

Blockade of 1- and desensitization of 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis

Delayed gastric emptying, gastroparesis-like symptoms, intestinal obstruction, biliary disease, and pancreatic safety concerns were variably reported, with heterogeneous and sometimes conflicting evidence across studies

As a result, industries that rely on unhealthy habits, such as tobacco and alcohol, could see a decline in demand

A provider who promises specific weight loss numbers is overpromising

Overall, therapeutic inertia was observed in 38.0% of the study population

Pre-clinical studies showed that anti-atherogenic effect of GLP-1 is independent of modulation of plasma lipid levels and depends on anti-inflammatory response